ABALOPARATIDE

Abaloparatide is a synthetic analogue of parathyroid hormone–related peptide (PTHrP). It is an anabolic (bone-forming) agent that increases bone mineral density by stimulating new bone formation, thereby reducing fracture risk.

Indications

- Treatment of osteoporosis in postmenopausal women at high risk of fracture - Patients with a history of osteoporotic fracture or multiple risk factors for fracture - who have failed or are intolerant to other osteoporosis therapies

Dosage

- Recommended dose: 80 micrograms once daily - Administered as a subcutaneous injection in the abdomen - Maximum recommended treatment duration: up to 2 years during a patient’s lifetime

Contra-Indications

- Hypersensitivity to abaloparatide or any component of the formulation - Patients with increased risk of osteosarcoma (e.g., Paget’s disease of bone, unexplained elevations of alkaline phosphatase, prior skeletal radiation therapy) - Patients with bone metastases or skeletal malignancies - Severe hypercalcemia

Special Precautions

- Use caution in patients with orthostatic hypotension, especially after the first few doses - Monitor serum calcium levels in patients with suspected hypercalcemia - Not recommended for use beyond 2 years due to potential risk of bone tumors - Not indicated for pediatric patients or premenopausal women

Side Effects

- Dizziness - Nausea - Headache - Palpitations - Fatigue - Injection-site reactions (redness, pain, swelling) - Hypercalciuria

Drug Interactions

- No major clinically significant drug interactions reported - Use caution with drugs affecting calcium metabolism (e.g., calcium supplements, vitamin D)